Longeveron Inc. (LGVN)

↓ Download CSV

CIK 0001721484 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Longeveron Inc. reported revenue of $1.20M, down 49.9% from the prior year. The company ran a net loss, with a net margin of -1893.6% and a gross margin of 67.0%. It held $10.26M in total assets against $4.59M in total liabilities.

Key ratios (FY2025)

67.0%
Gross margin
-1942.2%
Operating margin
-1893.6%
Net margin
-400.1%
Return on equity
-49.9%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019
Revenue$1.20M$2.39M$709.0K
Cost of Revenue$396.0K$508.0K$488.0K$725.0K$716.0K$3.80M
Gross Profit$803.0K$1.88M$221.0K$497.0K$590.0K$1.83M
Operating Income-$23.29M-$16.52M-$21.03M-$18.04M-$17.46M-$3.78M
Net Income-$22.70M-$15.97M-$21.41M-$18.84M-$17.05M-$3.72M
EPS (Diluted)$-1.29$-2.62$-10.22$-0.90$-0.90
Total Assets$10.26M$25.56M$12.08M$27.41M$42.77M$9.24M
Total Liabilities$4.59M$3.67M$5.34M$6.91M$5.31M$7.28M
Shareholders' Equity$5.67M$21.89M$6.74M$20.50M$37.45M$1.96M$4.4K
Cash & Equivalents$4.66M$19.23M$4.95M$10.50M$25.66M$816.0K
Operating Cash Flow-$18.64M-$13.87M-$19.00M-$13.97M-$9.64M-$2.36M
Capital Expenditures$245.0K$655.0K$301.0K$569.0K$330.0K$131.0K
Shares Outstanding17.58B9.41B2.17B20.97M18.92M